SecBot SecBot
SECBOTREPLAY Home › Report › AZN

AZN · AstraZeneca's Saphnelo (anifrolumab) has been approved by the FDA for…

ASTRAZENECA PLC · 6-K filed Apr 27, 2026 at 06:29 ET

At the news

BULLISHIMPACT 7/10

6-K filed Apr 27, 2026 at 06:29 ET

AstraZeneca's Saphnelo (anifrolumab) has been approved by the FDA for self-administration via a once-weekly autoinjector (Saphnelo Pen) for adult patients with systemic lupus erythematosus (SLE), expanding access beyond the current IV infusion. The approval is based on Phase III TULIP-SC trial data showing statistically significant and clinically meaningful reduction in disease activity.

  • FDA approved Saphnelo for subcutaneous self-administration using the Saphnelo Pen, a once-weekly autoinjector, for adult SLE patients on standard therapy.
  • Approval based on Phase III TULIP-SC trial results demonstrating statistically significant and clinically meaningful reduction in disease activity versus placebo.
  • Saphnelo Pen offers patients greater flexibility and convenience compared to the current IV infusion, potentially increasing adoption and market penetration.
  • Saphnelo IV is already approved in over 70 countries; subcutaneous formulation previously approved in EU and Japan.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access